Picard Medical, Inc. Stock Price, News & Analysis

Philip Morris International (NYSE: PM) urged the FDA advisory committee on October 7, 2025 to recommend continued marketing of IQOS as a modified risk tobacco product (MRTP). The FDA previously found evidence supporting the reduced-exposure claim for IQOS. PMI submitted renewal requests covering two device versions and three HEETS variants and highlighted global usage figures: ~34 million legal-age IQOS consumers as of June 30, 2025 and 41 million smoke-free product users globally. PMI stated its smoke-free business accounted for 41% of H1 2025 net revenues and noted ongoing FDA reviews for IQOS ILUMA (pending ~two years).

Picard Medical (NYSE American: PMI) has strengthened its intellectual property portfolio with the grant of U.S. Patent No. 12,383,722 B2 for its next-generation SynCardia Total Artificial Heart (STAH), dubbed the "Emperor." The company now holds 34 patented claims across three U.S. patents and has secured protection in China through Patent No. 115279450 B.

The Emperor represents a significant advancement as a fully implantable artificial heart that provides pulsatile flow without requiring an external pneumatic driver. This technology aims to revolutionize treatment options for end-stage heart failure patients, offering enhanced patient flexibility and improved quality of life.

Picard Medical (NYSE American: PMI), maker of the first U.S. and Canadian approved total artificial heart, reported significant Q2 2025 financial results. The company achieved 207% year-over-year revenue growth to $2.13 million, driven by strong U.S. product sales.

The company recently completed its IPO raising $19.5 million in gross proceeds. Despite revenue growth, Picard reported a net loss of $6.72 million in Q2 2025, compared to $4.06 million in Q2 2024, primarily due to increased non-cash debt expenses and derivative losses. The company's operating loss improved 8% to $3.52 million.

For the first half of 2025, revenue increased 3% to $2.74 million, while net loss widened to $12.29 million. Following the IPO, Picard expects to fund operations into 2026, focusing on artificial heart adoption and developing its next-generation Emperor platform.

Picard Medical (NYSE American: PMI), parent company of SynCardia Systems LLC, has announced the appointment of two new members to its Board of Directors following its initial public offering. The company, known for developing the first U.S. and Canadian commercially-approved total artificial heart, has appointed Sam Van and George Ye to strengthen its board leadership.

Sam Van, founder and CEO of SRO Partners, brings extensive capital markets experience from roles at Freedom U.S. Markets, NYSE, and various board positions. George Ye contributes significant medical device industry expertise from leadership positions at Edwards Lifesciences, Abbott Laboratories, and Johnson & Johnson, particularly in global markets.

Picard Medical (NYSE American: PMI) announced that underwriters have fully exercised their over-allotment option for the company's initial public offering. The option resulted in the issuance of an additional 637,500 shares at $4.00 per share, generating gross proceeds of $2.55 million.

The company's shares began trading on the NYSE American on August 29, 2025. WestPark Capital served as Lead Manager and Sole Bookrunner, with Sentinel Brokers as Co-Manager. E.F. Hutton and Uphorizon acted as financial advisors for the offering.

Picard Medical (NYSE American: PMI) announced its upcoming participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will be held from September 8-10, 2025, at the Lotte New York Palace Hotel in a hybrid format featuring both in-person and virtual sessions.

CEO Patrick NJ Schnegelsberg will deliver an in-person company presentation on September 10th at 1:30 pm. The presentation will be webcasted live and available for replay through Picard's website in the Investor Overview/Events section.

Picard Medical (NYSE American: PMI) has successfully completed its Initial Public Offering (IPO), raising $17 million in gross proceeds. The company offered 4,250,000 shares of common stock at $4.00 per share.

Trading of PMI shares commenced on the NYSE American exchange on August 29, 2025. The underwriters, led by WestPark Capital as Lead Manager and Sole Bookrunner, have a 30-day option to purchase up to 637,500 additional shares to cover potential over-allotments.

Picard Medical (NYSE American: PMI) has announced the pricing of its Initial Public Offering, offering 4,250,000 shares of common stock at $4.00 per share, aiming to raise $17 million in gross proceeds. The company, which manufactures the only FDA and Health Canada-approved total artificial heart (STAH), will begin trading on August 29, 2025.

The IPO includes a 30-day over-allotment option for underwriters to purchase up to 637,500 additional shares. WestPark Capital serves as Lead Manager and Sole Bookrunner. The proceeds will fund market expansion in China through SynCardia Medical (Beijing), product R&D including the Emperor system, sales and marketing capabilities enhancement, debt repayment, and general corporate purposes.

Philip Morris International (PMI) announces the relocation of its corporate headquarters to Stamford, Connecticut, with an expected opening in summer 2022. This move is poised to create approximately 200 jobs and contribute around $50 million to the state's economy. The 71,484 square foot facility will serve as a hub for PMI’s Americas region and amplify its commitment to a smoke-free future. PMI aims to transition to a majority smoke-free product portfolio by the end of 2025, with nearly 30% of net revenues coming from non-combustible products as of Q3 2021.